Actavis plc, an integrated pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. It offers generic, branded, branded generic, biosimilar, over-the-counter, biologic, and specialty pharmaceutical products in various formulations, including modified release, solid oral dosage, semi-solids, liquids, gels, transdermal products, and injectables; and develops and out-licenses generic pharmaceutical products to customers through its third-party business.
ACT Technical analysis
ACT is trading in the range of $144.00 – $166.00 in the past 30 days. The stock has been showing support at $154.00 and resistance in the $165.00 range. The stock is trading above the 50-Day Moving Average and above the 200-Day Moving Average. The RSI(14) is 63.51. Our indicators give a bullish view on ACT.